Pharmacopeia Inc

Pharmacopeia — Pharmacopeia Drug Discovery — Shareholder Meeting (May 2005)

17 slides from Pharmacopeia's shareholder meeting presentation, May 5, 2005

  1. Slide 1: Annual Meeting, Princeton, New Jersey, May 5th, 2005

    Slide 1: Annual Meeting, Princeton, New Jersey, May 5th, 2005

    HARMACOPEIA RUG DISCOVERY Annual Meeting Princeton, New Jersey May 5th, 2005

  2. Slide 2: Forward-Looking Statements

    Slide 2: Forward-Looking Statements

    Forward-Looking Statemen When used anywhere in this presentation, the words "expects," "believes," “articipates," "estimates" and similar expressions are intended to identity forward-looking statements. Forward-looking statements herein may include statements addressing future financial and operatin

  3. Slide 3: Pharmacopeia Drug Discovery

    Slide 3: Pharmacopeia Drug Discovery

    PHARMACOPEIA DRUG DISCOVERY Pharmacopeia Drug Discovery, Inc. is a biopharmaceutical company, focused on the creation of new small molecule therapeutics to address significant unmet medical needs PHARMACOPEIA

  4. Slide 4: Pharmacopeia Overview: PCOP Investment Drivers

    Slide 4: Pharmacopeia Overview: PCOP Investment Drivers

    Pharmacopeia Overview PCOP Investment Drivers + Comprehensive, integrated drug discovery capabilities + Proven track record of development success — 10 therapeutic candidates with 6 pharma collaborators + Future ‘annuity’ from broad partnered portfolio + Growing portfolio of small molecule drug cand

  5. Slide 5: Business Strategy

    Slide 5: Business Strategy

    Business Strategy Building a Clinical Portfolio + Discover and develop candidates to clinical validation * Build a portfolio of high value candidates fo treat immunological diseases « Partner at high value inflection points B&B PHARMACOPEIA

  6. Slide 6: Drugs in the Pipeline

    Slide 6: Drugs in the Pipeline

    Drugs in the el Advance intern pipeline to the « + ADME Tox * early product | * intellectual p 2 Evolve succes: collaboration 2005-2006 2007+ BB PHARMACOPEIA

  7. Slide 7: Validated Discovery Platform

    Slide 7: Validated Discovery Platform

    alidated Discovery Platform Lead Lead Pre-clinical Discovery 7) HtT9 Lead) optimization | Developmer Phase | Phase ll > BB PHARMACOPEIA

  8. Slide 8: Successful Discovery Business

    Slide 8: Successful Discovery Business

    ‘cessful Discovery Busines 10/5104 = Pharmacopeia Achieves Preclinical Development Candidate Milestone in Collaboration with Schering-Plough 10/25/04 Pharmacopeia Announces Expanded Collaboration with Neurocrine 10/26/04 Biovitrum AB and Pharmacopeia Form Strategic Research Alliance 1119104 Pharmaco

  9. Slide 9: Milestones today and royalties in the future

    Slide 9: Milestones today and royalties in the future

    Milestones today and royalties in the future Preciinica! Glinied Phrase Lead Now Program | Partner | censration | Ortimization | Cevelopment [| u wo | Pied Posio4s | Rheumatoid | Bristol Myer mee (tt Psancea | Aathmasiieay | Daiichi sree vu Pese2as | Respiratory | Soheine Plough > 9201622 | intammat

  10. Slide 10: Strategy

    Slide 10: Strategy

    Strategy + Evolve the successful collaboration drug discovery business — capture an increasing share of the downstream return + Advance and expand the portfolio of wholly- owned therapeutic product programs — rapidly bring drug candidates to clinical validation — partner at high value inflection poi

  11. Slide 11: Link to searchable text of slide shown above

    Slide 11: Link to searchable text of slide shown above

    Link to searchable text of slide shown above

  12. Slide 12: Robust Pipeline

    Slide 12: Robust Pipeline

    Robust Pipeline Multiple Product Partnered Opportunities Partnered + Internal Lead Optimization 18 Lead Discovery 21 Screening/Screen Development BB PHARMACOPEIA

  13. Slide 13: Therapeutic Focus

    Slide 13: Therapeutic Focus

    Therapeutic Foc! Rheumatoid Arthritis Multiple Sclerosis Inflammatory Ulcerative Colitis Bowel Disease Single target modulates multiple diseases BB PHARMACOPEIA

  14. Slide 14: Large Market Opportunities

    Slide 14: Large Market Opportunities

    Large Market Opportunities Market Size for Selected Inflammation Therapeutics US Market Only 2003 Revenues 8.0 TA 70 6.0 5 4g we a5 £ 5 240 a a 3.0 20 10 0.0 Asthma Rheumatoid Arthritis Psoriasis Inflammatory Bowel Diseases Source: Defined Health, 2004 BB PHARMACOPEIA

  15. Slide 15: PCOP Investment Drivers: Most Advanced Internal Programs

    Slide 15: PCOP Investment Drivers: Most Advanced Internal Programs

    PCOP Investmen ve Most Advanced Internal Programs * p38 kinase inhibitors + Phase | partnered with Bristol-Myers Squibb + Rheumatoid arthritis and other inflammatory diseases + Potentially best in class * avp3 / avp5 blockers + Pharmacopeia wholly-owned + Cancer, ocular and inflammation + Preclinica

  16. Slide 16: Financial Summary

    Slide 16: Financial Summary

    Financial Summa * 2004 Financial Data $24.4 MM in revenue $11.5 MM net loss, excluding restructuring charge $40.9 MM in cash on December 31, 2004 Cash burn May 1, 2004 — December 31, 2004 = $5.9MM « Forecasted Cash December 31, 2005 = $25 - 30MM + Valuation Data 12.4 MM shares outstanding Post spin

  17. Slide 17: Searchable text section of graphics shown above

    Slide 17: Searchable text section of graphics shown above

    Searchable text section of graphics shown above [ LOG O] Annual Meeting Princeton, New Jersey May 5th, 2005 [LOGO] For ward-Looking Statement When used anywhere in this presentation, the words “expects,” “believes,” “anticipates,” “estimates” and similar expressions are intended to identify forward-

Source: SEC EDGAR · 8-K filed May 5, 2005

More decks from Pharmacopeia Inc